IntegraGen specializes in researching and identifying genetic biomarkers, primarily in the field of oncology. The group offers high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups. France accounts for 84.4% of net sales.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-25	€0.0740	+0.27%	1,320
26-09-24	€0.0738	+0.27%	10,401
26-09-23	€0.0736	-0.27%	5,956
26-09-22	€0.0738	-1.86%	11,038
26-09-21	€0.0752	-0.27%	8,659

Real-time Euronext Paris

More quotes

Real-time Euronext Paris 05:24:19 2026-09-25 am EDT			5-day change	1st Jan Change
0.0740 ^EUR	+0.27%		-1.86%	-44.36%

Sep. 11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
Sep. 11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT

Market Cap	881K 1M 830K 757K 1.42M 96.1M 1.43M 9.96M 3.86M 48.91M 3.76M 3.68M 159M	P/E 2019	-23x	P/E 2020	-36.6x
Enterprise Value	-2.23M -2.53M -2.1M -1.92M -3.58M -243M -3.61M -25.21M -9.77M -124M -9.51M -9.31M -403M	EV / Sales 2019	0.49x	EV / Sales 2020	1.17x
Free-Float	32.13%	Yield 2019 *	-	Yield 2020	-

Markets		Quality
Euronext Paris	ALINT	Real-time
Börse Stuttgart	7N8	Delayed

Sep. 11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
Sep. 11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT
Jun. 16	IntegraGen Enters Receivership Proceedings
May. 28	IntegraGen to file for court-ordered receivership
Apr. 24	SSH Communications Security, Intragen Enter European Data Sovereignty Partnership	MT
Apr. 23	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-10-30	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-02	IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025	CI
25-07-02	IntegraGen SA Reports Sales Results for the First Half of 2025	CI
25-04-29	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-15	IntegraGen SA Announces Unaudited Revenue Results for the Year 2024	CI
24-10-18	IntegraGen: losses reduced, share price soars
24-07-29	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI

IntegraGen Stock

Stocks

ALINT

FR0010908723

Biotechnology & Medical Research

Valuation: IntegraGen

Chart: IntegraGen

Latest news: IntegraGen

Press Releases: IntegraGen

News in other languages: IntegraGen

Quotes and Performance

Price Extremes

Managers and Directors: IntegraGen

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

25-07-02	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	PU
25-07-02	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	BU
25-04-29	IntegraGen: 2024 Annual Results	BU
25-01-15	IntegraGen : Inside Information / Information on annual revenues	PU
25-01-15	IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m	BU

Sep. 14	Bourse : Capgemini vend sa division CGS, Euronext reparle consolidation et J&J pourrait céder son orthopédie
Sep. 14	La love story du marché avec l'IA connaît quelques ratés
Sep. 14	Deux offres de reprise déposées pour IntegraGen
Sep. 11	IntegraGen annonce le dépôt de deux offres de reprise dans le cadre de son redressement judiciaire
Jun. 16	Bourse : tensions entre Unicredit et l'Allemagne, SpaceX flambe (encore), Bénéteau au régime

1 day	+0.27%
1 week	-1.86%
Current month	-58.77%
1 month	-58.54%
3 months	-60.43%
6 months	-57.71%
Current year	-44.36%

1 week	0.07	0.08
1 month	0.07	0.24
Current year	0.07	0.36
1 year	0.07	0.36
3 years	0.07	1.32
5 years	0.07	2.04
10 years	0.07	4.29

Manager	Title	Age	Since
Bernard Courtieu CEO	Chief Executive Officer	62	2009-11-08
Virginie de Coster DFI	Director of Finance/CFO	-	2022-12-31
Berengere Genin COO	Chief Operating Officer	-	2023-12-31

Director	Title	Age	Since
Bernard Courtieu CHM	Chairman	62	2011-09-21
Jean-Pol Detiffe BRD	Director/Board Member	53	2020-12-31
François Blondel BRD	Director/Board Member	63	2023-12-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTEGRAGEN	+0.27%	-1.86%	-52.10%	-94.39%	553K
IOVANCE BIOTHERAPEUTICS, INC.	-0.14%	+6.49%	+440.35%	+138.84%	4.89B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+0.05%	+3.64%	+125.82%	+483.66%	4.72B
VERACYTE, INC.	-1.86%	+22.08%	+48.02%	+116.20%	3.9B
CAREDX, INC.	+0.33%	+12.86%	+308.57%	+695.22%	3.17B
BGI GENOMICS CO., LTD.	+2.50%	+20.93%	-9.18%	-15.52%	2.58B
FREENOME, INC.	+0.80%	-3.62%	+48.11%	-	1.72B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-2.75%	+8.46%	+181.04%	-18.71%	1.14B
SEEGENE, INC.	-0.58%	+0.89%	+30.52%	+61.14%	1.13B
CURIOX BIOSYSTEMS CO., LTD	+5.08%	+3.98%	-17.88%	+84.39%	623M
Average	+0.48%	+5.98%	+110.33%	+161.20%	2.39B
Weighted average by Cap.	+0.17%	+8.85%	+176.02%	+256.42%

	2019	2020
Net sales	8.28M 9.41M 7.81M 7.12M 13.32M 904M 13.42M 93.67M 36.3M 460M 35.34M 34.58M 1.5B	9M 10.23M 8.48M 7.74M 14.48M 982M 14.59M 102M 39.45M 500M 38.42M 37.58M 1.63B
Net income	-285K -324K -269K -245K -458K -31.08M -462K -3.22M -1.25M -15.82M -1.22M -1.19M -51.48M	-375K -426K -354K -323K -603K -40.92M -608K -4.24M -1.64M -20.83M -1.6M -1.57M -67.78M
Net Debt	-2.52M -2.86M -2.37M -2.17M -4.05M -275M -4.08M -28.49M -11.04M -140M -10.75M -10.52M -455M	-3.11M -3.53M -2.93M -2.67M -5M -339M -5.04M -35.17M -13.63M -173M -13.27M -12.98M -562M